Interview with Wolfgang Söhngen, CEO, Paion
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
Address: Martinstraße 10-12, 52062 Aachen,Germany
Tel: +49 241 4453-0
PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals, which was completed in June 2008, the company has a second site in Cambridge, UK.The company is specializing in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.PAION intends further expand its portfolio of drugs by exploiting its core expertise in identifying high-potential compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process.
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
See our Cookie Privacy Policy Here
